Amyloidosis

Amyloidosis is a general term for a group of diseases. In these diseases, abnormal proteins called amyloid build up in different parts of the body. These protein clumps can damage organs and tissues, leading to various symptoms depending on where they form.

Condition

What people with Amyloidosis report

Every report comes from a Lived member, sent anonymously.

Have you tried Vyndamax / Vyndaqel (Tafamidis) for Amyloidosis?

NameHow it went

About Amyloidosis

What It Is

Amyloidosis is a group of rare diseases in which a protein folds into the wrong shape, clumps into stiff fibers called amyloid and builds up in organs and tissues. The body cannot easily clear these deposits. As they accumulate, they crowd out normal tissue and make organs stiff, so the organ gradually stops working as it should. The heart, kidneys, nerves, liver and digestive tract are affected most often, and several organs can be involved at once. Amyloidosis is not one disease. Each type is named after the protein that forms the deposits, and the type decides the treatment. The most common are AL (light chain) amyloidosis, caused by abnormal antibody fragments from a small group of bone marrow cells; ATTR (transthyretin) amyloidosis, which comes from a carrier protein made mainly by the liver; and AA (amyloid A) amyloidosis, which follows years of uncontrolled inflammation. Most types spread through the body (systemic amyloidosis), but some stay in one place (localized amyloidosis). Early symptoms are often vague: tiredness, breathlessness, swollen legs, numb or tingling feet, or unexplained weight loss. As a result, amyloidosis is frequently recognized late, after an organ has already been damaged. Treatment works best when it starts before that damage is advanced.

Causes & Risk Factors

The cause depends on the type. AL amyloidosis starts with a small group of abnormal plasma cells, the antibody-making cells in the bone marrow. They overproduce pieces of antibody called light chains, which misfold and settle in organs. It is the most common type in the United States and is most often diagnosed after age 65. ATTR amyloidosis comes from transthyretin, a protein that carries thyroid hormone and vitamin A in the blood. In the wild-type form, the protein has no genetic change but still forms deposits, mainly in the heart; it occurs mostly in older adults, and most people diagnosed are men. The hereditary (variant) form is caused by a change in the TTR gene. One copy of the changed gene is enough to cause disease, so it can pass from a parent to a child. One variant that affects the heart is more common in people of African ancestry. A family history is often missing, especially when symptoms start later in life. AA amyloidosis develops after a long-lasting infection or inflammatory disease, such as rheumatoid arthritis, inflammatory bowel disease, familial Mediterranean fever or tuberculosis. Keeping that underlying inflammation under control lowers the chance of AA amyloidosis. A less common type affects people who have been on dialysis for many years, when a protein that dialysis does not fully remove builds up in bones, joints and tendons. Diet has not been shown to cause or prevent amyloidosis, and most types cannot be prevented.

How It's Diagnosed

Amyloidosis is usually suspected from a combination of clues rather than a single symptom. These include heart failure with a thickened heart wall, protein in the urine, numbness in the feet, an irregular heartbeat, carpal tunnel syndrome in both wrists, early fullness when eating, or unexplained weight loss. In ATTR amyloidosis, carpal tunnel syndrome can appear 5 to 9 years before heart symptoms, so it is one of the recognized early warning signs. Blood and urine tests look for an abnormal antibody protein, the hallmark of AL amyloidosis. A complete workup includes immunofixation of both blood and urine, which identifies an abnormal protein, and a serum free light chain test, which measures the two kinds of light chain and the ratio between them. A standard protein electrophoresis test on its own can miss the problem. Heart tests show whether the heart is involved: an electrocardiogram, an echocardiogram (an ultrasound of the heart), blood markers of heart strain and sometimes a cardiac MRI (magnetic resonance imaging) scan. Confirming the type usually requires a tissue sample. This may be a small needle sample of belly fat, a bone marrow biopsy or a biopsy of an affected organ such as the kidney or heart, and a specialized laboratory identifies which protein the deposits are made of. For suspected ATTR heart disease, a nuclear bone scan (imaging after a small injection of radioactive tracer) can make the diagnosis without a heart biopsy, but only after blood and urine tests have ruled out the abnormal protein of AL amyloidosis, because the scan cannot reliably tell the two apart. People with ATTR amyloidosis are usually offered genetic counseling and testing, whether or not relatives are known to be affected. Getting the type right is the most important step. AL and ATTR can look alike on heart tests but need entirely different treatment. Delays of months to more than two years are common, which is why a specialist familiar with amyloidosis is often involved.

Treatment Options

There is currently no cure for most types of amyloidosis, but treatment can slow or stop the buildup of new deposits, ease symptoms and improve quality of life. Treatment has two parts: cutting off the supply of the protein that forms amyloid, and supporting the organs that are already affected. AL amyloidosis is treated by a hematologist (blood specialist) with medicines that destroy the abnormal plasma cells, similar to those used for multiple myeloma. A common first treatment combines daratumumab (Darzalex Faspro, an antibody injected under the skin) with bortezomib, cyclophosphamide and the steroid dexamethasone. Some people whose heart and other organs are strong enough are offered high-dose chemotherapy followed by an autologous stem cell transplant, which returns their own previously collected stem cells. People with very advanced heart involvement may not tolerate standard treatment, which is one reason early diagnosis matters. For ATTR amyloidosis affecting the heart, two kinds of medicine are approved to reduce deaths and hospital stays from heart problems. Stabilizers hold the transthyretin protein together so it is less likely to break apart and form amyloid: tafamidis (Vyndaqel or Vyndamax, a capsule taken once a day) and acoramidis (Attruby, a tablet taken twice a day). Silencers lower how much transthyretin the liver makes: vutrisiran (Amvuttra) is given as an injection by a clinician every three months. For nerve damage from hereditary ATTR amyloidosis, vutrisiran, patisiran (Onpattro, an infusion into a vein) and eplontersen (Wainua, a monthly injection) are options. Silencers lower vitamin A levels, so people taking vutrisiran are advised to take a standard daily vitamin A supplement, not a higher dose. These medicines slow the disease; they are not a cure. AA amyloidosis is treated by controlling the inflammation or infection behind it, for example with anti-inflammatory biologic medicines for an inflammatory disease, or colchicine for familial Mediterranean fever. Supportive care matters for every type. Water pills (diuretics) and limiting salt help control fluid buildup, a pacemaker can treat heart rhythm problems, and kidney medicines or dialysis support failing kidneys. Some common heart medicines, including digoxin, calcium channel blockers and beta-blockers, need extra caution, because people with cardiac amyloidosis can be especially sensitive to their side effects. For selected people, a heart, kidney or liver transplant may be considered.

What to Expect

The course varies more than with most conditions because it depends on the type, which organs are involved and how much damage had occurred before diagnosis. Heart involvement has the largest effect on outlook. Cardiac amyloidosis was once regarded as untreatable and quickly fatal, but with current treatments many people now live for years with a good quality of life. Day to day, the most common burdens are fatigue, breathlessness with activity, swelling in the legs or belly, and lightheadedness when standing. Many people limit salt and fluids and weigh themselves each morning, because a quick rise in weight is often the first sign of fluid building up. Nerve involvement can cause numb feet, unsteady walking, and bowel, bladder or sexual problems. Care is usually shared among several specialists, such as cardiology, hematology, nephrology (kidney care) and neurology, with regular blood tests, heart and kidney checks, and treatment adjustments over time. ATTR medicines are taken long term. If the hereditary form is found, blood relatives can consider genetic counseling to decide whether testing makes sense for them.

When to Seek Help

Ask your doctor about amyloidosis if you have a combination of unexplained clues, such as heart failure with a thickened heart, protein in your urine, numbness or tingling in your feet, carpal tunnel syndrome in both hands, or unexplained weight loss with fatigue, or if a blood relative has hereditary ATTR amyloidosis. If you have amyloidosis, contact your care team right away about fainting spells, dizziness when you stand up, severe breathing problems, or sudden heavy weight loss. Call your care team soon about a weight gain of 3 pounds (about 1 kilogram) or more over 1 to 2 days, passing much less urine than usual, or swelling in your ankles or elsewhere that does not go away.

Questions to Ask Your Doctor

  1. 1.Which type of amyloidosis do I have, and how was the type confirmed?
  2. 2.Which organs are affected, and how will we track whether they are getting better or worse?
  3. 3.What can treatment realistically achieve for my type and stage, and what are the main trade-offs?
  4. 4.Should I have genetic testing, and what would the result mean for my relatives?
  5. 5.Do any of my current medicines need to change because of how amyloidosis affects my heart or kidneys?

Last reviewed • Oct 2026

Educational content, not medical advice.